pubmed-article:17700046 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:17700046 | lifeskim:mentions | umls-concept:C0035647 | lld:lifeskim |
pubmed-article:17700046 | lifeskim:mentions | umls-concept:C0003289 | lld:lifeskim |
pubmed-article:17700046 | lifeskim:mentions | umls-concept:C1269683 | lld:lifeskim |
pubmed-article:17700046 | lifeskim:mentions | umls-concept:C0035020 | lld:lifeskim |
pubmed-article:17700046 | lifeskim:mentions | umls-concept:C0178602 | lld:lifeskim |
pubmed-article:17700046 | lifeskim:mentions | umls-concept:C0301630 | lld:lifeskim |
pubmed-article:17700046 | pubmed:issue | 5 | lld:pubmed |
pubmed-article:17700046 | pubmed:dateCreated | 2007-8-16 | lld:pubmed |
pubmed-article:17700046 | pubmed:abstractText | Whether the dose of antidepressants can be reduced following clinical improvement without subsequently increasing the likelihood of depressive relapse has not been established. Thus, the aim of this work was to compare relapse rates among patients with major depressive disorder (MDD) randomized to either continue receiving the full versus a reduced dose of antidepressants following partial or full improvement of symptoms. | lld:pubmed |
pubmed-article:17700046 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17700046 | pubmed:language | eng | lld:pubmed |
pubmed-article:17700046 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17700046 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:17700046 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17700046 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:17700046 | pubmed:issn | 0033-3190 | lld:pubmed |
pubmed-article:17700046 | pubmed:author | pubmed-author:PapakostasGeo... | lld:pubmed |
pubmed-article:17700046 | pubmed:author | pubmed-author:FavaMaurizioM | lld:pubmed |
pubmed-article:17700046 | pubmed:author | pubmed-author:PerlisRoy HRH | lld:pubmed |
pubmed-article:17700046 | pubmed:author | pubmed-author:SeifertCheryl... | lld:pubmed |
pubmed-article:17700046 | pubmed:copyrightInfo | 2007 S. Karger AG, Basel | lld:pubmed |
pubmed-article:17700046 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:17700046 | pubmed:volume | 76 | lld:pubmed |
pubmed-article:17700046 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:17700046 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:17700046 | pubmed:pagination | 266-70 | lld:pubmed |
pubmed-article:17700046 | pubmed:dateRevised | 2009-11-11 | lld:pubmed |
pubmed-article:17700046 | pubmed:meshHeading | pubmed-meshheading:17700046... | lld:pubmed |
pubmed-article:17700046 | pubmed:meshHeading | pubmed-meshheading:17700046... | lld:pubmed |
pubmed-article:17700046 | pubmed:meshHeading | pubmed-meshheading:17700046... | lld:pubmed |
pubmed-article:17700046 | pubmed:meshHeading | pubmed-meshheading:17700046... | lld:pubmed |
pubmed-article:17700046 | pubmed:meshHeading | pubmed-meshheading:17700046... | lld:pubmed |
pubmed-article:17700046 | pubmed:meshHeading | pubmed-meshheading:17700046... | lld:pubmed |
pubmed-article:17700046 | pubmed:meshHeading | pubmed-meshheading:17700046... | lld:pubmed |
pubmed-article:17700046 | pubmed:meshHeading | pubmed-meshheading:17700046... | lld:pubmed |
pubmed-article:17700046 | pubmed:year | 2007 | lld:pubmed |
pubmed-article:17700046 | pubmed:articleTitle | Antidepressant dose reduction and the risk of relapse in major depressive disorder. | lld:pubmed |
pubmed-article:17700046 | pubmed:affiliation | Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, Mass. 02114, USA. gpapakostas@partners.org | lld:pubmed |
pubmed-article:17700046 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:17700046 | pubmed:publicationType | Meta-Analysis | lld:pubmed |
pubmed-article:17700046 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17700046 | lld:pubmed |